Scribe Therapeutics
NASDAQ: SCTXBerkeley, US · Founded 2017 · Delaware corporation · 6 known investors
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions. The company uses advanced engineering of natural CRISPR systems to create targeted genetic medicines.
Founders & leadership
Scribe Therapeutics was founded in 2017 by Benjamin Oakes, Jennifer A. Doudna, PhD, Benjamin L. Oakes, PhD, David F. Savage, PhD, and Brett Staahl, PhD.
BO
Benjamin OakesFounder & CEO
JA
Jennifer A. Doudna, PhDCo-founder, Scientific Advisor
BL
Benjamin L. Oakes, PhDCo-founder, President and CEO
DF
David F. Savage, PhDCo-founder, Scientific Advisor
BS
Brett Staahl, PhDCo-founder, VP of External Innovation
Board
VP
Vijay Pandein𝕏Member Board Of Directors2018–2025General Partner, Andreessen Horowitz at Propagator Ventures
CG
BA
Investors · 6
Reported raises · per SEC filings
Form D private placements$100M disclosed across 1 round · 2021
▶$100MraisedApr 2021 · 19 investors · Other TechnologyRule 506(b)
▶$100MraisedApr 2021 · 19 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Benjamin OakesExecutive Officer, Director
- Vijay PandeDirector
- Carl GordonDirector
- Behzad AghazadehDirector
- Offering amount
- $100M
- Amount sold
- $100M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapCRISPR31 shared keywordsCRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology. It is led by a management team, board of directors, and scientific founders from the biotech and pharmaceutical industries.
Scribeamerica28 shared keywordsScribeAmerica, in partnership with Speke AI, provides medical scribe services and an AI-powered clinical documentation platform that helps healthcare professionals capture patient encounters and reduce administrative work. The tool offers custom note templates, support for 30+ languages, and EHR integrations, and is available on iOS, Android, and desktop.
Epicrispr Biotechnologies26 shared keywordsEpicrispr Biotechnologies develops therapies that dynamically control gene expression using the epigenome to treat complex diseases. Its Gene Expression Modulation System (GEMS) platform combines epigenomic modulators to build therapies customized for specific disease indications.
Scribe26 shared keywordsScribe automatically captures and documents work processes, converting institutional knowledge into accessible workflows that teams and AI agents can reference. The platform enables organizations to identify inefficiencies, scale best practices, and integrate workflow data with AI tools for training and automation.
Companies competing with Scribe Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Early-stage Scribe wants to write IPO story even as investors favor derisked portfolios - BioSpacebiospace.com · Jul 2026
Scribe Therapeutics Files Nasdaq IPO With $180Mallsci.com · Jul 2026Frequently asked questions
- What does Scribe Therapeutics do?
- Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions. The company uses advanced engineering of natural CRISPR systems to create targeted genetic medicines.
- Who founded Scribe Therapeutics?
- Scribe Therapeutics was founded by Benjamin Oakes, Jennifer A. Doudna, PhD, Benjamin L. Oakes, PhD, David F. Savage, PhD, Brett Staahl, PhD in 2017.
- Who are Scribe Therapeutics's investors?
- Scribe Therapeutics's investors include Andreessen Horowitz, OrbiMed, Avoro Capital Advisors, Menlo Ventures, RA Capital, Avoro Ventures.
- How much funding has Scribe Therapeutics raised?
- Scribe Therapeutics has disclosed $100M raised across 1 round.
- Where is Scribe Therapeutics headquartered?
- Scribe Therapeutics is headquartered in Berkeley, US.